Structure Therapeutics Inc. detailed its approach to addressing the growing demand for obesity treatments, highlighting the scalability and accessibility of oral small molecule therapies compared to current injectable GLP-1 options. The company noted that despite over 100 million adults in the U.S. affected by overweight and obesity, current injectable treatments reach less than 5% of the addressable market. Structure Therapeutics projects significant market growth driven by broader access, improved affordability, new oral modalities, and expanding patient awareness. Internal and third-party estimates suggest that by 2030, 25-50% of the U.S. anti-obesity medication market could be served by oral therapies, appealing particularly to needle-hesitant adults and non-specialist prescribers. The company emphasized the convenience and potential cost benefits of oral treatments, as well as the increasing role of telehealth and primary care providers in obesity management. You can access the full presentation through the link below.